1. Introduction: 4CMenB schedule in adolescents
- Two doses one month apart needed (Phase II/III trials), unlikely cost-effective in the UK
- From 2026, UK 11+ years old will have received 3 doses in infancy (2+1)
- Persistence? Potential for a single dose in >11 years to induce sufficient serum bactericidal antibodies?

- Recruit at 11 years old to receive a single dose (day 0)
- Age-matched vaccine-naïve controls to receive a single dose (day 0) or a full 2-doses adolescent schedule (day 0 and 28)
- Serum bactericidal antibody responses against indicator strains at day 0, and at months 1, 6 and 12

3. Results: hSBA
- Proportion of participants with titer >= 1:4 and CI
- Individual titers, with group geometric mean and CI

4. Conclusions
- Small sample size ➔ descriptive study
- Booster doses well tolerated
- B cell memory responses are not adequately primed <12 months of age

Acknowledgements: Meningitis Research Foundation (MRF, meningitis.org), award 1702, and by the NIHR Oxford Biomedical Research Center (BRC) Vaccine theme